Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development

Aims To Commercialize Its Own Products

25 Nov 2020

• By John Davis

Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.

Cityscape of Copenhagen — Copenhagen, where Genmab is headquartered • Source: Shutterstock

Genmab A/S is not going to advance an antibody-drug conjugate, enapotamab vedotin, into late-stage clinical development, citing stringent proof-of-concept criteria, thereby cementing the biotech’s late-stage clinical development focus on two other potential anticancers, tisotumab vedotin and epcoritamab.

Enapotamab vedotin’s initial promise has not been backed up by early clinical studies, the Copenhagen, Denmark-based company said on 24...